HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0.

Abstract
Immunological phenotyping of acute leukemia have provided enormous and important information for the classification and lineage determination of leukemia. Forty-nine patients with CD7(+) CD56(+) acute myeloid leukemia (AML) were analyzed. There were 17 patients of M0, which corresponded to myeloid/NK cell precursor acute leukemia, and 32 patients of AML other than M0 (9 each for M1 and M2, one for M3, 3 for M4, 4 for M5 and 6 for M7). Age distribution was similar between these two groups, but CD7(+) CD56(+) M0 showed significant male predominance than CD7(+) CD56(+) M1-M7 (M:F = 15:2 vs. 15:17, P = 0.006). The disease localization and the hematological manifestations were different, showing fewer white blood cell counts and circulating leukemic blasts, less anemia, less thrombocytopenia and more frequent extramedullary involvement in M0 group. The prognosis was poor in both groups, and there was no statistical difference. These findings suggest that extramedullary involvement of myeloid/NK cell precursor acute leukemia is not directly derived from the presence of CD7 and CD56 antigens on leukemic cells. The poor prognosis of CD7(+) CD56(+) M1-M7 suggests that this phenotype may act as a prognostic factor for AML, but this should be confirmed in further studies.
AuthorsRitsuro Suzuki, Shigeki Ohtake, Jin Takeuchi, Masami Nagai, Yoshihisa Kodera, Motohiro Hamaguchi, Shuichi Miyawaki, Takahiro Karasuno, Shigetaka Shimodaira, Ryuzo Ohno, Shigeo Nakamura, Tomoki Naoe
JournalInternational journal of hematology (Int J Hematol) Vol. 91 Issue 2 Pg. 303-9 (Mar 2010) ISSN: 1865-3774 [Electronic] Japan
PMID20111912 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD7
  • Biomarkers, Tumor
  • CD56 Antigen
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone
Topics
  • Adolescent
  • Adult
  • Aged
  • Antigens, CD7 (metabolism)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Biomarkers, Tumor (metabolism)
  • CD56 Antigen (metabolism)
  • Cyclophosphamide (therapeutic use)
  • Data Collection
  • Disease-Free Survival
  • Doxorubicin (therapeutic use)
  • Female
  • Flow Cytometry
  • Humans
  • Immunophenotyping
  • Leukemia, Myeloid, Acute (drug therapy, metabolism, mortality)
  • Leukocyte Count
  • Male
  • Middle Aged
  • Prednisone (therapeutic use)
  • Prognosis
  • Remission Induction
  • Sex Distribution
  • Survival Analysis
  • Vincristine (therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: